Latest California Healthline Stories
$89,000 Orphan Drug Gets A New Owner — And Likely A New Price
Marathon, maker of an expensive treatment for Duchenne muscular dystrophy, sells the drug for $140 million in cash and stock to PTC Therapeutics.
HMO Doctors Take Pains To Slash Opioid Prescriptions
A Kaiser Permanente pain management program in Southern California aims to help patients taper off addictive painkillers. Some doctors and patients see it as a godsend; others complain that patients have been cut off medications they need.
To Save On Drug Costs, Insurer Wants To Steer You To ‘Preferred’ Pharmacies
Blue Shield of California is hoping to steer consumers to “preferred” pharmacies where drugs are cheaper and copays lower.
Trump, Dems Look For Common Ground On Drug Prices
Two Democratic congressmen met with President Trump to seek his support for a bill to expand the government’s ability to negotiate drug prices, but it’s not clear it would have much impact or will gain support.
President Trump And I Take The Same Drugs — Except One
An aging writer discovers there are worse things than going bald after examining the side effects of a popular hair loss drug purportedly used by President Donald Trump.
Geriatricians Can Help Aging Patients Navigate Multiple Ailments
Aging adults with complex needs can get special assistance from doctors trained as geriatricians.
Health Law’s 10 Essential Benefits: A Look At What’s At Risk In GOP Overhaul
The woman set to run the federal Centers for Medicare & Medicaid Services told senators last week that maternity coverage should be optional in individual and small group plans. But other services could also be left on the cutting room floor.
Docs In Northwest Tweak Aid-In-Dying Drugs To Prevent Prolonged Deaths
Some terminal patients, typically high-dose opioid users, who choose to end their lives have taken many hours, even days, to die.
Former FDA Chief Cites 5 Things To Watch On Drug Approvals, And Keeping Drugs Safe
Former FDA Commissioner Dr. Robert Califf shares his views about drug approvals, regulations and safety concerns after stepping down from the giant agency.
Drugmaker Marathon ‘Pausing’ Delivery Of $89,000-a-year Muscular Dystrophy Drug
After hearing complaints about its high price, Marathon Pharmaceuticals is pausing the launch of an $89,000 drug for a rare disease.